[Something new in the genetics of monogenic obesity and its insights into pathophysiology].

Du nouveau dans la génétique des formes monogéniques d’obésité et son impact pour mieux en comprendre la physiopathologie.

Journal

Medecine sciences : M/S
ISSN: 1958-5381
Titre abrégé: Med Sci (Paris)
Pays: France
ID NLM: 8710980

Informations de publication

Date de publication:
Oct 2020
Historique:
entrez: 7 10 2020
pubmed: 8 10 2020
medline: 13 11 2020
Statut: ppublish

Résumé

Obesity is a complex, multifactorial disorder. About 5% of obese patients actually present with a monogenic form of obesity where only one mutation is sufficient to cause the disease. So far, the genes that have been found to be mutated in these monogenic forms play a key role in the leptin/melanocortin pathway which is mainly active in the hypothalamus and which regulates food intake and energy expenditure. Our laboratory has recently reported a novel monogenic form of obesity due to MRAP2 deficiency where, contrary to previously described monogenic forms of obesity, the carriers presented with hyperglycemia and hypertension in addition to obesity, suggesting that MRAP2 might play a pleiotropic role in metabolic tissues, in addition to its role in brain control of food intake and energy expenditure. Du nouveau dans la génétique des formes monogéniques d’obésité et son impact pour mieux en comprendre la physiopathologie. L’obésité est une maladie complexe multifactorielle. Chez environ 5 % des individus obèses, il existe des formes monogéniques d’obésité pour laquelle une seule mutation est suffisante pour entraîner la maladie. Jusqu’à présent, les gènes mutés identifiés dans ces formes monogéniques sont impliqués dans la voie leptine/mélanocortine, principalement active au niveau de l’hypothalamus et régissant la satiété. Récemment, notre laboratoire a décrit une nouvelle forme monogénique d’obésité. Elle est due à une déficience du gène MRAP2 (melanocortin-2 receptor accessory protein 2) pour laquelle, contrairement aux formes précédemment décrites, on retrouve chez les porteurs une hyperglycémie et une hypertension, suggérant que MRAP2 joue un rôle biologique général dans les tissus métaboliques en plus de son rôle dans l’hypothalamus.

Autres résumés

Type: Publisher (fre)
Du nouveau dans la génétique des formes monogéniques d’obésité et son impact pour mieux en comprendre la physiopathologie.

Identifiants

pubmed: 33026327
doi: 10.1051/medsci/2020156
pii: msc200132
doi:

Substances chimiques

Leptin 0
MC4R protein, human 0
Receptor, Melanocortin, Type 4 0
Receptors, Leptin 0
Pro-Opiomelanocortin 66796-54-1

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

859-865

Informations de copyright

© 2020 médecine/sciences – Inserm.

Références

Matta J, Zins M, Feral-Pierssens A, et al. Prévalence du surpoids, de l’obésité et des facteurs de risque cardio-métaboliques dans la cohorte Constances. Bull Epidémiol Hebd 2016 ; 35–36 : 640–646.
Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju SN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016 ; 388 : 776–786.
Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020; 28(7) : 1195–9.
Wardle J, Carnell S, Haworth CM, et al. Evidence for a strong genetic influence on childhood adiposity despite the force of the obesogenic environment. Am J Clin Nutr 2008 ; 87 : 398–404.
Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide association studies for height and body mass index in ≈700000 individuals of European ancestry. Hum Mol Genet 2018 ; 27 : 3641–3649.
Ndiaye FK, Huyvaert M, Ortalli A, et al. The expression of genes in top obesity-associated loci is enriched in insula and substantia nigra brain regions involved in addiction and reward. Int J Obes (Lond) 2020; 44 : 539–43.
Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994 ; 372 : 425–432.
Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995 ; 1 : 1155–1161.
Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997 ; 387 : 903–908.
Clément K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998 ; 392 : 398–401.
Ellacott KLJ, Cone RD The role of the central melanocortin system in the regulation of food intake and energy homeostasis: lessons from mouse models. Philos Trans R Soc Lond, B, Biol Sc 2006 ; 361 : 1265–1274.
Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature 2006 ; 443 : 289–295.
Arora S Anubhuti null. Role of neuropeptides in appetite regulation and obesity: a review. Neuropeptides 2006 ; 40 : 375–401.
Vaisse C, Clement K, Guy-Grand B, et al. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 1998 ; 20 : 113–114.
Yeo GS, Farooqi IS, Aminian S, et al. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 1998 ; 20 : 111–112.
Stutzmann F, Tan K, Vatin V, et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes 2008 ; 57 : 2511–2518.
Saeed S, Arslan M, Froguel P Genetics of obesity in consanguineous populations: toward precision medicine and the discovery of novel obesity genes. Obesity (Silver Spring) 2018 ; 26 : 474–484.
Dubern B, Bisbis S, Talbaoui H, et al. Homozygous null mutation of the melanocortin-4 receptor and severe early-onset obesity. J Pediatr 2007; 150 : 6137, 617.e1.
Krude H, Biebermann H, Luck W, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998 ; 19 : 155–157.
O’Rahilly S, Gray H, Humphreys PJ, et al. Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 1995 ; 333 : 1386–1390.
Philippe J, Stijnen P, Meyre D, et al. A nonsense loss-of-function mutation in PCSK1 contributes to dominantly inherited human obesity. Int J Obes 2015 ; 39 : 295–302.
Tolson KP, Gemelli T, Gautron L, et al. Postnatal Sim1 deficiency causes hyperphagic obesity and reduced Mc4r and oxytocin expression. J Neurosc. 2010 ; 30 : 3803–3812.
Bonnefond A, Raimondo A, Stutzmann F, et al. Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features. J Clin Invest 2013 ; 123 : 3037–3041.
Ramachandrappa S, Raimondo A, Cali AMG, et al. Rare variants in single-minded 1 (SIM1) are associated with severe obesity. J Clin Invest 2013 ; 123 : 3042–3050.
Yeo GSH, Connie Hung CC, Rochford J, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 2004 ; 7 : 1187–1189.
Gray J, Yeo G, Hung C, et al. Functional characterization of human NTRK2 mutations identified in patients with severe early-onset obesity. Int J Obes (Lond) 2007 ; 31 : 359–364.
Gray J, Yeo GSH, Cox JJ, et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 2006 ; 55 : 3366–3371.
Serra-Juhé C, Martos-Moreno GÁ, Bou de Pieri F, et al. Heterozygous rare genetic variants in non-syndromic early-onset obesity. Int J Obes (Lond) 2020; 44 : 830–41.
Doche ME, Bochukova EG, Su H-W, et al. Human SH2B1 mutations are associated with maladaptive behaviors and obesity. J Clin Invest 2012 ; 122 : 4732–4736.
Siljee JE, Wang Y, Bernard AA, et al. Subcellular localization of MC4R with ADCY3 at neuronal primary cilia underlies a common pathway for genetic predisposition to obesity. Nat Genet 2018 ; 50 : 180–185.
Saeed S, Bonnefond A, Tamanini F, et al. Loss-of-function mutations in ADCY3 cause monogenic severe obesity. Nat Genet 2018 ; 50 : 175–179.
Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999 ; 341 : 879–884.
Kühnen P, Clément K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med 2016 ; 375 : 240–246.
Clément K, Biebermann H, Farooqi IS, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med 2018 ; 24 : 551–555.
Collet TH, Dubern B, Mokrosinski J, et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab 2017 ; 6 : 1321–1329.
Montagne L, Derhourhi M, Piton A, et al. CoDE-seq, an augmented whole-exome sequencing, enables the accurate detection of CNVs and mutations in Mendelian obesity and intellectual disability. Mol Metab 2018 ; 13 : 1–9.
Chan LF, Webb TR, Chung TT, et al. MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. Proc Natl Acad Sci USA 2009 ; 106 : 6146–6151.
Asai M, Ramachandrappa S, Joachim M, et al. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. Science 2013 ; 341 : 275–278.
Sebag JA, Zhang C, Hinkle PM, et al. Developmental control of the melanocortin-4 receptor by MRAP2 proteins in zebrafish. Science 2013 ; 341 : 278–281.
Baron M, Maillet J, Huyvaert M, et al. Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension. Nat Med 2019 ; 25 : 1733–1738.

Auteurs

Morgane Baron (M)

Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Université de Lille, CHU de Lille, 1 place de Verdun, 59045, France.

Philippe Froguel (P)

Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Université de Lille, CHU de Lille, 1 place de Verdun, 59045, France - Department of Metabolism, Imperial College London, Londres, W12 0NN, Royaume-Uni.

Amélie Bonnefond (A)

Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Université de Lille, CHU de Lille, 1 place de Verdun, 59045, France - Department of Metabolism, Imperial College London, Londres, W12 0NN, Royaume-Uni.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH